Company: CDT
Filing Date: 2025-02-05
Form Type: S-3
Source: 0001493152-25-005052
Chunk: 2

Company: CDT Equity Inc.
Filing Date: 2025-02-05
Form: S-3
Chunk 2
---
 sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED FEBRUARY 5, 2025</div>

PRELIMINARY PROSPECTUS

<div align='center'>5,800,000 Shares of Common Stock Underlying the Convertible Note

28,625 Shares of Common Stock Underlying A.G.P. Warrants

22,727 Shares of Common Stock issued pursuant to the Sarborg Services Agreement

47,353 Shares of Common Stock issued pursuant to the Miscellaneous Issuances</div>

This prospectus relates to the offer and resale of up to an aggregate of 5,898,705 shares of common stock, par value $0.0001 per share (the “Common Stock”) of Conduit Pharmaceuticals Inc. (the “Company,” “we,” “our” or “us”), held by the selling stockholders listed in this prospectus or its permitted transferees (the “Selling Stockholders”). The shares of Common Stock registered for resale pursuant to this prospectus (the “Shares”) consist of (i) 5,800,000 Shares that may be issued, assuming the minimum conversion price, upon the conversion of the A.G.P. November 2024 convertible promissory note (the “Convertible Note”), into shares of Common Stock, at the discretion of A.G.P./Alliance Global Partners (“A.G.P.”); (ii)28,625 Shares underlying warrants issued to A.G.P. on October 29, 2024 (the “A.G.P. Warrants”) pursuant to that certain Bridge Loan Agreement dated October 29, 2024 (the “A.G.P. Bridge Agreement”), entered into between the Company and A.G.P; (iii) 22,727 Shares issued pursuant to the Services Agreement (the “Sarborg Services Agreement”) entered into on December 12, 2024 by and between SARBORG Limited (“Sarborg”) and the Company;and (iv) 47,353 Shares (the “Miscellaneous Issuances”) consisting of: (a) 8,161 Shares issued pursuant to a Consulting Agreement entered into by and between the Company and Jack Heilbron on November 8, 2022 (the “Heilbron Consulting Agreement”); (b) 27,812 Shares issued in satisfaction of obligations the Company incurred under the Loan Extension Amendment entered into on September 20, 2024 (the “Isayan Loan Amendment”) by and between